Stories about what is happening in our market.
The newest edition of Sponsor Atlas: Discovering Biotech Startups takes a look at Menlo Park's stealth biotech, Ignite Biosciences
Funding activity in Massachusetts for July 2019
The first edition of Sponsor Atlas: Discovering Biotech Startups takes a look at Pittsburgh's stealth biotech, BlueSphere Bio
Funding activity in Masschusetts for June 2019
A recap of some mergers and acquisitions across pharma/biotech in May 2019
Which Japanese drug sponsors were the most active in the past year? Let's find out!
Welcome back to Flagged Events: M&A, where we recap some of the latest mergers & acquisition activities across pharma for the month.
Merck & Co. is an American pharmaceutical company, ranked 4th internationally in the world in terms of 2017 prescription sales . It is important to note that Merck & Co. is a wholly separate and independent company from the German company Merck KGaA, despite the fact that the two share a common origin and brand name.
A look at some of the M&A activity across pharma to kick off 2019!
The latest edition of the Sponsor Atlas series takes a look at Israel's generics giant, Teva Pharmaceuticals.
Born from the 1989 merger between Denmark’s top two insulin producers, Novo Nordisk markets products to over 165 countries. Learn how and where they make decisions about outsourcing activities in clinical research, contract manufacturing, logistics, and more.
The latest edition of our Sponsor Atlas: Selling to the Pharma Giants series, where we are taking a look at AstraZeneca.
Let's take a look at the most active clinical study registrants in France!
In this edition of Sponsor Atlas: Selling to the Pharma Giants, we're visiting New York City's biopharma behemoth, Bristol-Myers Squibb (BMS). Their three-part name was born in 1989 merger between the Squibb Corporation and the Bristol-Myers Corporation, two NYC-based pharmaceutical companies founded in 1858 and 1887, respectively.
Part 2 of our Sponsor Atlas: Selling to the Pharma Giants blog series. It's off to Germany for the latest stop on our expedition, to visit Bayer and understand how they make their outsourcing decisions and how best to find opportunities.
For this edition of our Sponsor Pipeline Insights, we're taking a trip up to the American Northeast to check out the top 10 most active clinical study registrants.
We live in a time where lists make up much of the content that appears in our timelines each day. So, why not ride the wave? Everybody loves a good list, after all! Here's a list of the top 10 most active drug sponsor companies in New York State.
(10/05/2015) There isn’t much out there about California’s newest biotech company, but here are a few clues to set you on your way.
Choosing the right software tools for your team is a difficult task, especially when operating on a limited budget. Making smart decisions about what your team will actually use can lead to higher effectiveness.
(02/07/2014) We often get asked the question “how much prospecting should my Business Development team be doing?” The answer to this comes down to deciding what you want your sales pipeline to look like and how comfortable you are with risking a drought in deal flow.
(04/08/2015) Contract Research and Investment Organizations (CRIOs) are an emerging entity in the biotech drug development space that can have an unforeseen impact on your team’s sales productivity. This article discusses critical considerations for teams that encounter a CRIO deal—ten real examples are included as a starting point to better understand this trend.
Do your sales & marketing teams stand united or divided?
Prospecting is typically a dreaded part of the sales process. It goes something like this: Identify target companies. Search LinkedIn to see if you know anyone at the company. Place cold calls or send out generic emails and hope that you get a response. Rinse and repeat.
A guide to GDPR for service provider companies selling to pharmaceutical & biotech companies in Europe. With strict new regulations being implemented, how can you reach your potential customers?
(09/28/2014) With Coherus Biosciences’ $86 Million IPO announced last week, we wanted to take a closer look at the companies that stand to benefit the most from the upcoming injection of capital.
Multinational giants like Novartis can be a tough sell for service provider companies when they don't know where to target. Understanding where decisions about different kinds of outsourced activities take place can help you close more new business. Join us for part one of our new series Sponsor Atlas: Selling to the Pharma Giants!
Guest post by Ty Quinn. The Contract Research Organization (CRO) sector is complex. Business Development professionals are required to maintain accurate and organized records of any/all accounts, contacts, interactions and opportunities and to be able to call on them at a moment’s notice.